Potent Antiretroviral Therapy Initiates Normalization of Hypergammaglobulinemia and a Decline in HIV Type 1-Specific Antibody Responses
- 20 July 2001
- journal article
- research article
- Published by Mary Ann Liebert Inc in AIDS Research and Human Retroviruses
- Vol. 17 (11) , 1003-1008
- https://doi.org/10.1089/088922201300343681
Abstract
Next to a profound T cell immunodeficiency, HIV-1 infection induces activation and dysfunction of B cells, resulting in hypergammaglobulinemia. Whereas T cell immune reconstitution with potent antiretroviral therapy has been extensively documented, limited data are available on B cell immune reconstitution. We studied the effect of potent antiretroviral therapy on antibody titers to the viral proteins gp120 and p24 and on total IgG concentrations. Three retrospectively chosen groups were studied: a successfully treated group, untreated controls, and subjects with virological failure after several months of successful therapy. In the successfully treated group, the median total IgG concentrations normalized, whereas they remained elevated in the untreated group and rebounded after an initial decline in the therapy failure group. The HIV-1-specific antibody titers declined in the successfully treated group and followed the rebound of the HIV RNA levels in the therapy failure group. With potent antiretroviral therapy the hypergammaglobulinemia normalized whereas HIV-1-specific immune responses were weakened. The weakening of antiviral immunity with therapy may be relevant for current attempts to gain immunological control over the virus through structured treatment interruptions or therapeutic vaccinations.Keywords
This publication has 37 references indexed in Scilit:
- Evaluation of a Second-Generation Nucleic Acid Sequence-Based Amplification Assay for Quantification of HIV Type 1 RNA and the Use of Ultrasensitive Protocol AdaptationsAIDS Research and Human Retroviruses, 2000
- Immune Reconstitution after 2 Years of Successful Potent Antiretroviral Therapy in Previously Untreated Human Immunodeficiency Virus Type 1–Infected AdultsThe Journal of Infectious Diseases, 1999
- HIV-1 Antigen–specific and –nonspecific B Cell Responses Are Sensitive to Combination Antiretroviral TherapyThe Journal of Experimental Medicine, 1998
- Quantitation of HIV-1-Specific Cytotoxic T Lymphocytes and Plasma Load of Viral RNAScience, 1998
- Decrease of HIV-1 RNA levels in lymphoid tissue and peripheral blood during treatment with ritonavir, lamivudine and zidovudineAIDS, 1998
- Immunological abnormalities in human immunodeficiency virus (HIV)-infected asymptomatic homosexual men. HIV affects the immune system before CD4+ T helper cell depletion occurs.Journal of Clinical Investigation, 1988
- Temporal relation of antigenaemia and loss of antibodies to core antigens to development of clinical disease in HIV infection.BMJ, 1987
- Persistent HIV antigenaemia and decline of HIV core antibodies associated with transition to AIDS.BMJ, 1986
- Antibodies to HTLV-III in Swiss Patients with AIDS and Pre-AIDS and in Groups at Risk for AIDSNew England Journal of Medicine, 1985
- Abnormalities of B-Cell Activation and Immunoregulation in Patients with the Acquired Immunodeficiency SyndromeNew England Journal of Medicine, 1983